193000-39-4 Usage
Uses
Used in Pharmaceutical Industry:
ZM 323881 hydrochloride is used as an anticancer agent for targeting and inhibiting vascular endothelial growth factor receptor-2 (VEGFR-2). This inhibition helps in disrupting the angiogenesis process, which is essential for tumor growth and progression. By blocking VEGFR-2, ZM 323881 hydrochloride can potentially limit the supply of nutrients and oxygen to the tumor, thereby hindering its growth and spread.
Additionally, ZM 323881 hydrochloride may be used in combination with other chemotherapeutic drugs to enhance their efficacy and overcome resistance in cancer treatments. Its selective targeting of VEGFR-2 could also reduce the side effects associated with non-selective drugs, improving the overall treatment experience for patients.
Check Digit Verification of cas no
The CAS Registry Mumber 193000-39-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,3,0,0 and 0 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 193000-39:
(8*1)+(7*9)+(6*3)+(5*0)+(4*0)+(3*0)+(2*3)+(1*9)=104
104 % 10 = 4
So 193000-39-4 is a valid CAS Registry Number.
193000-39-4Relevant articles and documents
Chemical compounds
-
Example 70, (2010/11/29)
The invention relates to quinazoline derivatives of the formula: [wherein: Y1represents —O—, —S—, —CH2—, —SO—, —SO2—, —NR5CO—, —CONR6—, —SO2NR7—, —NR8SO2— or —NR9— (wherein R5, R6, R8and R9each independently represents hydrogen, alkyl or alkoxyalkyl); R1represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, alkyl, alkoxy, alkylthio, amino or alkylamino. R2represents hydrogen, hydroxy, halogeno, alkyl, alkoxy, trifluoromethyl, cyano, amino or nitro; m is an integer from 1 to 5; R3represents hydroxy, halogeno, alkyl, alkoxy, alkanoyloxy, trifluoromethyl, cyano, amino or nitro; R4represents a group which is or which contains an optionally substituted pyridone, phenyl or aromatic heterocyclic group] and salts thereof; processes for their preparation and pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
